Sana Biotechnology (NASDAQ:SANA) Sets New 12-Month Low – Should You Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as $2.27 and last traded at $2.27, with a volume of 401977 shares changing hands. The stock had previously closed at $2.48.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SANA. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Sana Biotechnology in a research note on Wednesday, November 27th. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th.

Sana Biotechnology Trading Down 5.2 %

The company’s 50-day simple moving average is $3.28 and its 200-day simple moving average is $4.80. The stock has a market capitalization of $524.68 million, a price-to-earnings ratio of -1.63 and a beta of 1.33.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. On average, equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Sana Biotechnology

In other news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. The trade was a 5.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 31.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its position in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after purchasing an additional 4,438,949 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sana Biotechnology by 9.6% in the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after acquiring an additional 276,055 shares in the last quarter. State Street Corp grew its stake in Sana Biotechnology by 4.2% in the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after acquiring an additional 269,274 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock valued at $6,552,000 after acquiring an additional 220,000 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock valued at $1,325,000 after acquiring an additional 178,179 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.